Among patients with relapsing multiple sclerosis, 450 mg of ublituximab could be safely infused in 30 minutes at week 24.

Credit: Getty Images In a post hoc analysis, researchers assessed the maintenance of the efficacy and safety of transitioning from IV anti-CD20 therapy to ofatumumab by race/ethnicity subgroup in ...

InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today that the phase II results of orelabrutinib ...

TG Therapeutics will announce its financial results for this period in a press release to be issued prior to the call.

Immunic, Inc. , a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and ...

Emalex Biosciences’ dopamine blocker led to fewer patients with Tourette syndrome relapsing in a phase 3 trial, setting the ...

Immunic Presents Key Vidofludimus Calcium Data at the ACTRIMS Forum 2025, Highlighting Its Potential in Multiple Sclerosis – Vidofludimus Calcium’s Activation of Nurr1 Reduces ...

By Mongabay.com The Madras hedgehog, found only in southern India, is considered a species of least concern on the IUCN Red ...

Discover a study where patients initially receiving placebo experienced notable improvement after switching to tildrakizumab.

China unveiled a comprehensive policy blueprint for rural development on Sunday, charting a detailed roadmap to build up the ...

Alcohol Justice has released its February 2025 eNews, a comprehensive roundup of the latest news, research, and advocacy ...

A person’s precious organ donation came with an unexpected visitor. In a new paper out this month, scientists have documented ...